Phosphodiesterase 5 inhibition improves beta-cell function in metabolic syndrome.
Abstract
OBJECTIVE: This study tested the hypothesis that phosphodiesterase 5 inhibition alone
or in combination with ACE inhibition improves glucose homeostasis and fibrinolysis
in individuals with metabolic syndrome. RESEARCH DESIGN AND METHODS: Insulin sensitivity,
beta-cell function, and fibrinolytic parameters were measured in 18 adults with metabolic
syndrome on 4 separate days after a randomized, crossover, double-blind, 3-week treatment
with placebo, ramipril (10 mg/day), tadalafil (10 mg o.d.), and ramipril plus tadalafil.
RESULTS: Ramipril decreased systolic and diastolic blood pressure, ACE activity, and
angiotensin II and increased plasma renin activity. Ramipril did not affect insulin
sensitivity or beta-cell function. In contrast, tadalafil improved beta-cell function
(P = 0.01). This effect was observed in women (331.9 +/- 209.3 vs. 154.4 +/- 48.0
32 micro x mmol(-1) x l(-1), respectively, for tadalafil treatment vs. placebo; P
= 0.01) but not in men. There was no effect of any treatment on fibrinolysis. CONCLUSIONS
Phosphodiesterase 5 inhibition may represent a novel strategy for improving beta-cell
function in metabolic syndrome.
Type
Journal articleSubject
AdultAngiotensin-Converting Enzyme Inhibitors
Blood Pressure
Carbolines
Cross-Over Studies
Double-Blind Method
Female
Humans
Insulin-Secreting Cells
Male
Metabolic Syndrome X
Phosphodiesterase 5 Inhibitors
Phosphodiesterase Inhibitors
Ramipril
Renin
Tadalafil
Permalink
https://hdl.handle.net/10161/13549Published Version (Please cite this version)
10.2337/dc08-1862Publication Info
Hill, Kevin D; Eckhauser, Aaron W; Marney, Annis; & Brown, Nancy J (2009). Phosphodiesterase 5 inhibition improves beta-cell function in metabolic syndrome.
Diabetes Care, 32(5). pp. 857-859. 10.2337/dc08-1862. Retrieved from https://hdl.handle.net/10161/13549.This is constructed from limited available data and may be imprecise. To cite this
article, please review & use the official citation provided by the journal.
Collections
More Info
Show full item recordScholars@Duke
Kevin Dennis Hill
Professor of Pediatrics
Clinical research including outcomes, drug and device trials, short and long term
safety and efficacy of interventions and hemodynamic effects of interventions.

Articles written by Duke faculty are made available through the campus open access policy. For more information see: Duke Open Access Policy
Rights for Collection: Scholarly Articles
Works are deposited here by their authors, and represent their research and opinions, not that of Duke University. Some materials and descriptions may include offensive content. More info